PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Glyxambi (Linagliptin/empagliflozin) - Diabetes Mellitus

PAD Profile : Glyxambi (Linagliptin/empagliflozin) - Diabetes Mellitus

Keywords :
Type II, glycaemic control, dipeptidyl peptidase 4, DPP-4 inhibitors, gliptins, sodium-glucose co-transporter 2, SGLT-2
Brand Names Include :
Glyxambi

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
03 June 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

This drug is currently not on the APC workplan. The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Please contact your local CCG Medicines Management team formulary pharmacist or chief pharmacist at your acute trust, if you wish to make a submission.

Associated BNF Codes

06. Endocrine System
06.01.02. Antidiabetic drugs
06.01.04. Treatment of hypoglycaemia
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More